Eli Lilly and Company (LLY)
In Lilly vs Novo obesity drug battle, Trump price talks grab focus
As obesity drug heavyweights Eli Lilly and Novo Nordisk gear up to release results for the third quarter, investors are looking elsewhere: high-stakes price talks with U.S. President Donald Trump.
What's the Driving Force Behind Eli Lilly's Recent Acquisition Spree?
LLY's rapid dealmaking spree across biotech and gene therapy aims to expand its pipeline beyond cardiometabolic drugs and fuel long-term growth.
Is It Worth Investing in Lilly (LLY) Based on Wall Street's Bullish Views?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
LLY Stock To $1,100?
Eli Lilly (LLY) shares have surged by 16% over the last month and are currently priced at $825. U.S. pharmaceutical stocks have done well of late, as large drugmakers such as Pfizer and AstraZeneca signed drug pricing agreements with the Trump Administration to cut prescription drug prices and boost domestic manufacturing investments.
Eli Lilly: Is Another Monster Quarter Coming
October 30th is the day when Eli Lilly will report its third-quarter results, including sales of its 'superstars' Zepbound and Mounjaro. Since my article was published on September 8, Eli Lilly's stock price has risen by 13.1%. On October 24th, Eli Lilly surprised me by announcing its acquisition of Adverum Biotechnologies, a developer of gene therapies for the treatment of ocular diseases, for up to $261.7 million.
Here's How Eli Lilly's Oncology Drugs Are Poised Ahead of Q3 Earnings
LLY's oncology portfolio, led by Verzenio, is set for double-digit growth as investors eye Q3 results beyond its obesity drugs.
Eli Lilly reports promising data for alopecia and eczema drugs, eyes label expansion
Eli Lilly announced on Friday safety and efficacy results from two separate late-stage studies testing its approved drugs for alopecia and eczema.
Lilly Up 10% in a Month: Should You Buy, Sell or Hold the Stock?
Lilly stock climbs nearly 10% in a month amid a broader recovery in the drug and biotech sector.
Eli Lilly Q3 earnings eyed for insights into drug pricing policies, obesity and diabetes drug performance
Eli Lilly and Co (NYSE:LLY) will report its third quarter 2025 earnings next Thursday, with Bank of America analysts closely watching how the company's obesity and diabetes treatments are performing amid ongoing policy debates over US drug pricing. The firm believes the drugmaker's upcoming report could offer insight into the company's key brands while highlighting broader industry trends affecting margins and growth.
J.L. Bainbridge Buys $45 Million in Eli Lilly Stock Despite Price-Pressure Fears
Florida-based wealth advisory J. L. Bainbridge disclosed a purchase of Eli Lilly and Company valued at approximately $45.6 million for the quarter ended September 30, according to an SEC filing released on Friday.
Investment Advisor Goes All-In on Big Pharma Stock to the Tune of $1.07 Billion, According to Recent Filing
On October 17, 2025, Sapient Capital LLC disclosed a purchase of 259,392 Eli Lilly and Company (LLY -1.94%) shares, for a total transaction value of $193,028,908.
3 Price Catalysts For Eli Lilly
Eli Lilly (NYSE:LLY) is up by ~30% since I last checked on it in August, with further upside potential remaining. Three potential developments can catalyse the stock further to achieve this upside, or not. An agreement with the US government on tariffs and further positive trial results can spark a rally for LLY.
